

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 0.6 ppm to 0.568% by weight of zinc, 33-57% by weight of P_2O_5 , 10-65% by weight of CaO and 0-28% by weight of H_2O , and having a sedimentation velocity of 0.8 cm/s or lower.

2. (Currently amended) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 120 ppm to 0.568% by weight of zinc, 33-57% by weight of P_2O_5 , 10-65% by weight of CaO and 0-28% by weight of H_2O , and having a sedimentation velocity of 0.8 cm/s or lower.

3. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, wherein said microparticle of zinc-containing calcium phosphate comprises one or more compounds selected from zinc-containing hydroxyapatite, zinc-containing poorly-crystallized apatite, zinc-containing α -tricalcium phosphate, zinc-containing β -tricalcium phosphate, zinc-containing calcium hydrogenphosphate, zinc-containing amorphous calcium phosphate and $CaZn_2(PO_4)_2 \cdot nH_2O$ ($0 \leq n \leq 2$).

4. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, further comprising at least one osteogenic compound

selected from vitamin D, α -calcidol, estrogen-related preparations, calcitonin, bisphosphonate and calcium containing preparations.

5. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, wherein said liquid comprises one or more water-miscible solvents selected from physiological saline solution, an aqueous solution of 2.5% by weight or less of sodium chloride, Ringer's solution, purified water, distilled water for injection, distilled water, physiological salt solution, propylene glycol, and ethanol.

6. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, wherein said liquid comprises one or more water-immiscible solvents selected from triglyceride, safflower oil, soybean oil, sesame oil, rapeseed oil, peanut oil, and polyethylene glycols (Macrogol).

7. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.

8. (Previously presented) The suspension or particle-solvent mixture system according to claim 4, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency and as an osteogenetic agent.

9. (Previously presented) The suspension or particle-solvent mixture system according to claim 3, further comprising at least one osteogenic compound

selected from vitamin D, α -calcidol, estrogen-related preparations, calcitonin, bisphosphonate and calcium containing preparations.

10. (Previously presented) The suspension or particle-solvent mixture system according to claim 3, wherein said liquid comprises one or more water-miscible solvents selected from physiological saline solution, an aqueous solution of 2.5% by weight or less of sodium chloride, Ringer's solution, purified water, distilled water for injection, distilled water, physiological salt solution, propylene glycol, and ethanol.

11. (Previously presented) The suspension or particle-solvent mixture system according to claim 4, wherein said liquid comprises one or more water-miscible solvents selected from physiological saline solution, an aqueous solution of 2.5% by weight or less of sodium chloride, Ringer's solution, purified water, distilled water for injection, distilled water, physiological salt solution, propylene glycol, and ethanol.

12. (Previously presented) The suspension or particle-solvent mixture system according to claim 3, wherein said liquid comprises one or more water-immiscible solvents selected from triglyceride, safflower oil, soybean oil, sesame oil, rapeseed oil, peanut oil, and polyethylene glycols (Macrogol).

13. (Previously presented) The suspension or particle-solvent mixture system according to claim 4, wherein said liquid comprises one or more water-immiscible solvents selected from triglyceride, safflower oil, soybean oil, sesame oil, rapeseed oil, peanut oil, and polyethylene glycols (Macrogol).

14. (Previously presented) The suspension or particle-solvent mixture system according to claim 3, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.

15. (Previously presented) The suspension or particle-solvent mixture system according to claim 4, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.

16. (Previously presented) The suspension or particle-solvent mixture system according to claim 5, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.

17. (Previously presented) The suspension or particle-solvent mixture system according to claim 6, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.

18. (New) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 0.6 ppm to 13% by weight of zinc, 33-57% by weight of P_2O_5 , 10-65% by weight of CaO and 0-28% by weight of H_2O , wherein said microparticle comprises zinc-containing calcium phosphate glass.

19. (New) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 0.6ppm to 13% by weight of zinc, 33-57% by weight of P_2O_5 , 10-65% by weight of CaO and 0-28% by weight of H_2O , and having a sedimentation velocity of 0.8 cm/s or lower, wherein the zinc-containing calcium phosphate does not comprise zinc-containing β -tricalcium phosphate or $CaZn_2(PO_4)_2$.

20. (New) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 0.6ppm to 13% by weight of zinc, 33-57% by weight of P_2O_5 , 10-65% by weight of CaO and 0-28% by weight of H_2O , and having a sedimentation velocity of 0.8 cm/s or lower, wherein said microparticle of zinc-containing calcium phosphate comprises one or more compounds selected from zinc-containing calcium hydrogenphosphate, zinc-containing amorphous calcium phosphate, zinc-containing α -tricalcium phosphate, zinc-containing poorly-crystallized apatite, $CaZn_2(PO_4)_2 \cdot H_2O$, and $CaZn_2(PO_4)_2 \cdot 2H_2O$.